Pharmaceutical

CMN-005 by CoImmune for Nodal Marginal Zone B-Cell Lymp...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Primary Mediastinal B-Cell Lymp...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Refractory Chronic Lymphocytic ...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

CMN-005 by CoImmune for Relapsed Chronic Lymphocytic Le...

CMN-005 is under clinical development by CoImmune and currently in Phase II for ...

Investment opportunities in atopic dermatitis may drive...

The atopic dermatitis market is facing increased growth, with a projected market...

Men taking valproate and their partners warned to use c...

A study suggests that children may face a higher risk of harm if their father is...

GSK’s asthma blockbuster Nucala secures win in COPD Pha...

GSK is adding more strings to Nucala’s bow as the drug’s sales continue to grow.

FDA grants ODD to Abdera’s neuroendocrine carcinoma tre...

The US FDA has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD...

NImmune and BioTherapeutics partner on precision medici...

NImmune Biopharma and BioTherapeutics have partnered to develop new precision me...

Evotec partners X-Chem for tech-enabled drug discovery

German life science company Evotec has announced a collaboration with X-Chem to ...

FDA approves Amneal and Shilpa’s oncology product BORUZU

The US FDA has approved Amneal Pharmaceuticals and Shilpa Medicare’s oncology pr...

Biogen’s higher Spinraza dose shows better efficacy in ...

Biogen plans to apply for regulatory approval of this investigational dose regim...

After failed FSGS bid, Travere wins full FDA approval f...

The company had focused its resources on Filspari’s launch in IgAN after the US ...

NHS England offers MSD belzutifan for von Hippel-Lindau...

NHS England has announced the availability of MSD UK’s belzutifan, a take-at-hom...